Oncotarget cover image

Genetic Study Identifies Potential Diagnostic Marker for Rare Blood Cancer BPDCN

Oncotarget

00:00

Clinical Impact and Risk Stratification

Speaker 0 discusses how CCDC50 and mutations like TET2/ASXL1 could aid diagnosis, monitoring, and personalized risk assessment.

Play episode at 02:47
Transcript

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app